Table 3 Treatment interaction with radiomic signature and pathological stage for DMFS in patients with LARC.

From: Predicting distant metastasis and chemotherapy benefit in locally advanced rectal cancer

 

CT

No CT

Distant metastases-free survival

CT vs NO CT, HR (95%CI)

p

p value for interaction

All (n = 629)

High RS

176

103

1.71 (1.13–2.57)

0.01

2.54 × 10−37

Low RS

230

120

0.75 (0.27–2.12)

0.59

pT = 0 (n = 66)

High RS

13

10

4.22 (0.49–36.16)

0.15

0.102

Low RS

24

19

1.55 (0.14–17.09)

0.72

pT = 1/2 (n = 106)

High RS

29

20

11.66 (1.53–88.83)

0.003

4.13 × 10−13

Low RS

33

24

NA

0.23

pT = 3/4 (n = 457)

High RS

134

73

1.25 (0.81–1.93)

0.32

5.09 × 10−29

Low RS

173

77

0.76 (0.22–2.59)

0.66

pN = 0 (n = 359)

High RS

83

58

2.67 (1.27–5.60)

0.007

1.43 × 10−11

Low RS

130

88

1.33 (0.24–7.26)

0.74

pN = 1 (n = 174)

High RS

58

27

1.15 (0.57–2.30)

0.70

2.76 × 10−17

Low RS

68

21

0.91 (0.09–8.70)

0.93

pN = 2 (n = 96)

High RS

35

18

1.16 (0.57–2.35)

0.68

1.67 × 10−31

Low RS

32

11

0.18 (0.03–1.06)

0.03

  1. RS radiomic signature, CT chemotherapy, HR hazard ratio, CI confidence interval.
  2. p values were calculated using two-sided log-rank test.